Mainland Chinese institutional fund managers have significantly increased their stakes in Hong Kong-listed biotechnology stocks over the past month, driven by a combination of attractive valuations and a surge in cross-border licensing deals.
The shift in capital allocation signals growing confidence in the sector's commercialization potential, as mainland investors seek exposure to innovative drug pipelines listed in the international hub.
Analysts note that the biotech sector is trading at relatively cheap levels compared to historical averages, making it an appealing target for value-oriented institutional capital.
The influx of mainland money coincides with a broader recovery in Hong Kong's capital markets, where initial public offering and secondary listing proceeds surged 84.3% year-on-year to US$26.4 billion in the first half of the year.
This renewed liquidity has supported a more favorable environment for growth-oriented sectors like biotech, which had previously faced headwinds from tighter financing conditions.
The rise in cross-border licensing deals further underpins the investment thesis, as Hong Kong-based biotech firms increasingly partner with mainland pharmaceutical companies to commercialize their assets.